TrialBlood2011

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.

Paola Guglielmelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.